Develops and manufactures plant-based biopharmaceuticals, including vaccines and therapeutic proteins, using its proprietary FastPharming System.
iBio, Inc., a prominent biotechnology firm based in Bryan, Texas, specializes in providing comprehensive contract development and manufacturing services within the United States. The company operates through two distinct segments: Biopharmaceuticals and Bioprocessing. In its Biopharmaceuticals segment, iBio focuses on advancing innovative therapeutic candidates, including its lead anti-fibrotic agent, IBIO-100. This candidate is currently undergoing development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis, addressing significant unmet medical needs in fibrotic diseases.
Alongside its therapeutic endeavors, iBio is actively engaged in vaccine development. Notably, it is developing IBIO-202, a vaccine candidate targeting the Nucleocapsid (N) protein to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Additionally, the company is advancing IBIO-400 for the treatment of classical swine fever. Beyond proprietary research, iBio extends its expertise in recombinant protein production to third-party collaborations. The company offers a comprehensive suite of services encompassing process development, manufacturing, and bioanalytical support.
Founded in 2008, iBio has forged strategic partnerships and licensing agreements with prominent institutions such as the University of Pittsburgh, The Texas A&M University System, and the University of Natural Resources and Life Sciences, Vienna. These alliances underscore iBio's commitment to leveraging cutting-edge biopharmaceutical technologies. Headquartered in Bryan, Texas, iBio continues to expand its footprint in the biotechnology sector, driven by a mission to advance transformative therapies and vaccines to improve global health outcomes.